News

SDL Announces General Availability of SDL Multilingual Submission Management

Solution Developed Specifically for Global Multilingual Regulatory Submissions

Maidenhead, UK

10/24/2017

SDL (LSE: SDL) has announced the availability of SDL Multilingual Submission Management (MSM), a web-based platform that enables biopharmaceutical firms to globally automate the submission of multilingual marketing authorization applications to regulatory authorities across 100+ languages and markets. 

Operating in one of the most demanding and highly regulated environments, pharmaceutical organizations face the constant challenge of filing, updating and maintaining medicinal product information globally. High standards demanded by local regulatory agencies during the submissions process – which varies by country – puts enormous pressure on firms to ensure every element of their application is flawless. Formatting and translation errors can delay timelines by weeks or even months. 

SDL MSM enables these organizations to overcome all the multilingual challenges associated with regulatory labelling and submission, providing the industry’s first dedicated platform for centrally managing this process globally. Based on market validated technologies that have helped many pharmaceutical organizations manage their global regulatory labelling submissions for the past decade, SDL MSM also combines a rich set of features that make it simple to manage the complete submission process from a single dashboard. 

“Submitting local language documents for regulatory approval with one regulatory agency is difficult enough – let alone across dozens of countries where documents need to be translated, reformatted, and orchestrated in a timely fashion,” said Kaarin Gordon, SVP of global life sciences, SDL. “Our proven success in this area for the past decade – combined with the exciting new web-based features that SDL MSM offers – make it a powerful platform to overcome one of the biggest burdens for international regulatory affairs departments.” 

Announced at the Global Pharmaceutical Regulatory Affairs Summit, Prague, SDL MSM offers easier, faster and lower cost deployment – with greater availability of services.

Get in touch

About RWS

RWS Holdings plc is the world’s leading provider of technology-enabled language, content management and intellectual property services. We help our customers to connect with and bring new ideas to people globally by communicating business critical content at scale and enabling the protection and realization of their innovations. 


Our vision is to help organizations interact effectively with people anywhere in the world by solving their language, content and market access challenges through our collective global intelligence, deep expertise and smart technology. 


Customers include 90 of the globe’s top 100 brands, the top 10 pharmaceutical companies and 18 of the top 20 patent filers worldwide. Our client base spans Europe, Asia Pacific, and North and South America across the technology, pharmaceutical, medical, legal, chemical, automotive, government and telecommunications sectors, which we serve from offices across five continents. 


Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L). 


For further information, please visit: www.rws.com.